An investigation for investors in NASDAQ:PTCT shares over potential securities laws violations by PTC Therapeutics and certain of its directors and officers was announced.
Investors who purchased shares of PTC Therapeutics, Inc. (NASDAQ:PTCT), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of PTC Therapeutics, Inc. (NASDAQ:PTCT) concerning whether a series of statements by PTC Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) grew from $15.07 per share in May 2014 to as high as $73.27 per share in March 2015.
On February 23, 2016, PTC Therapeutics, Inc. announced that it received a Refuse to File letter from the United States Food and Drug Administration (“FDA”) regarding PTC Therapeutics’ New Drug Application (“NDA”) for Translarna™ (ataluren), an oral, first-in-class, protein restoration therapy for the treatment of nonsense mutation Duchenne muscular dystrophy (“nmDMD”). Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) declined to as low as $10.11 per share.
On February 25, 2016, NASDAQ:PTCT shares closed at $7.98 per share.
Those who purchased NASDAQ:PTCT shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com